Double maintains 3 strategies that include GKOS - Glaukos Corp.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
PFUT | 65.80% | $375.92M | 0.65% |
FNY | 65.74% | $372.07M | 0.7% |
ARKF | 65.40% | $1.20B | 0.75% |
VBK | 65.31% | $18.97B | 0.07% |
IWO | 65.17% | $11.48B | 0.24% |
IWP | 64.99% | $22.01B | 0.23% |
ARKK | 64.92% | $6.89B | 0.75% |
VXF | 64.79% | $22.24B | 0.05% |
FXL | 64.30% | $1.36B | 0.62% |
BUZZ | 63.94% | $62.35M | 0.76% |
XSW | 63.83% | $492.02M | 0.35% |
QGRO | 63.82% | $1.72B | 0.29% |
IMCG | 63.73% | $2.76B | 0.06% |
FPX | 63.72% | $947.29M | 0.61% |
ISCG | 63.65% | $679.06M | 0.06% |
VOT | 63.59% | $16.94B | 0.07% |
QQQJ | 63.25% | $613.07M | 0.15% |
JMOM | 63.04% | $1.70B | 0.12% |
KOMP | 63.03% | $2.28B | 0.2% |
ARKW | 63.02% | $2.10B | 0.82% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -55.67% | $99.76M | 0.59% |
BTAL | -50.59% | $296.79M | 1.43% |
VIXY | -50.31% | $165.69M | 0.85% |
IVOL | -30.67% | $351.30M | 1.02% |
SPTS | -26.93% | $5.78B | 0.03% |
FXY | -24.49% | $815.67M | 0.4% |
SCHO | -24.48% | $11.46B | 0.03% |
VGSH | -23.35% | $22.80B | 0.03% |
XONE | -22.48% | $585.86M | 0.03% |
UTWO | -22.35% | $379.36M | 0.15% |
IEI | -21.39% | $15.37B | 0.15% |
IBTI | -21.29% | $1.06B | 0.07% |
BWX | -21.16% | $1.53B | 0.35% |
FTSD | -20.89% | $231.79M | 0.25% |
IBTJ | -20.76% | $685.71M | 0.07% |
TPMN | -20.71% | $30.77M | 0.65% |
IBTK | -20.58% | $442.63M | 0.07% |
VGIT | -19.85% | $31.83B | 0.04% |
IBTL | -19.76% | $380.68M | 0.07% |
IBTG | -19.25% | $1.92B | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HOOD | 62.16% | $73.27B | +265.61% | 0.00% |
SYF | 60.52% | $25.20B | +40.26% | 1.58% |
TRMB | 59.83% | $18.05B | +35.28% | 0.00% |
AIT | 59.34% | $8.82B | +19.43% | 0.71% |
EVR | 59.02% | $10.40B | +29.02% | 1.19% |
GS | 58.09% | $211.97B | +52.73% | 1.69% |
EQH | 58.06% | $17.01B | +36.96% | 1.75% |
OWL | 57.94% | $12.17B | +9.58% | 3.91% |
CG | 57.88% | $18.48B | +27.45% | 2.70% |
WEAV | 57.61% | $618.75M | -8.76% | 0.00% |
KKR | 57.25% | $119.60B | +27.60% | 0.52% |
PH | 56.94% | $89.51B | +38.50% | 0.95% |
COF | 56.58% | $135.08B | +52.41% | 1.13% |
CCL | 56.54% | $35.77B | +45.62% | 0.00% |
SOFI | 56.52% | $18.99B | +159.91% | 0.00% |
WCC | 56.51% | $9.05B | +16.99% | 0.93% |
ITT | 56.50% | $12.43B | +22.27% | 0.85% |
MS | 56.25% | $225.71B | +44.76% | 2.62% |
STEP | 56.07% | $4.31B | +23.25% | 1.70% |
TPG | 56.05% | $7.33B | +28.08% | 3.27% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FXC | -0.02% | $92.55M | 0.4% |
NUAG | -0.05% | $58.57M | 0.19% |
IBDT | 0.15% | $2.86B | 0.1% |
SCHJ | 0.21% | $528.03M | 0.03% |
SPSB | -0.34% | $8.32B | 0.04% |
GSY | 0.45% | $2.73B | 0.22% |
JSI | 0.47% | $865.43M | 0.49% |
MUB | -0.50% | $38.46B | 0.05% |
TBIL | 0.53% | $5.84B | 0.15% |
DFCF | -0.58% | $7.08B | 0.17% |
PYLD | -0.64% | $5.82B | 0.69% |
CANE | -0.66% | $10.44M | 0.29% |
IBDZ | -0.80% | $356.24M | 0.1% |
IBMN | -0.82% | $446.95M | 0.18% |
IBMP | -0.83% | $553.29M | 0.18% |
LTPZ | 0.89% | $672.84M | 0.2% |
BIL | -0.92% | $42.87B | 0.1356% |
KCCA | -0.94% | $104.88M | 0.87% |
YEAR | -1.02% | $1.45B | 0.25% |
KRBN | -1.05% | $163.57M | 0.85% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
VOD | 0.04% | $25.87B | +18.94% | 4.63% |
PPL | 0.16% | $24.81B | +21.37% | 3.18% |
STG | 0.20% | $29.06M | -28.79% | 0.00% |
CLX | 0.20% | $14.68B | -12.70% | 4.10% |
KHC | -0.20% | $30.31B | -20.52% | 6.25% |
TAK | 0.22% | $47.52B | +16.69% | 4.33% |
UUU | -0.25% | $6.64M | +78.38% | 0.00% |
IMNN | -0.29% | $15.04M | -36.21% | 0.00% |
KLG | 0.29% | $1.38B | -2.79% | 4.08% |
CELH | -0.32% | $11.84B | -19.62% | 0.00% |
KDP | 0.35% | $44.62B | -1.65% | 3.46% |
FDP | 0.36% | $1.54B | +46.73% | 3.42% |
VSA | -0.38% | $8.67M | -15.70% | 0.00% |
BTI | -0.51% | $102.80B | +51.83% | 8.07% |
NGG | 0.53% | $72.07B | +29.44% | 4.20% |
REYN | -0.57% | $4.48B | -23.87% | 4.32% |
SOHU | 0.58% | $392.95M | -6.11% | 0.00% |
GFI | -0.68% | $20.47B | +53.49% | 2.38% |
MOH | 0.68% | $16.10B | -0.08% | 0.00% |
MSIF | 0.83% | $769.00M | +36.08% | 6.63% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -27.14% | $23.98B | +34.66% | 1.10% |
ED | -26.03% | $35.36B | +9.76% | 3.39% |
TEF | -22.01% | $29.29B | +23.28% | 6.30% |
AWK | -21.96% | $26.90B | +6.78% | 2.27% |
AEP | -16.17% | $54.73B | +16.78% | 3.58% |
GIS | -16.06% | $27.66B | -20.14% | 4.74% |
MKTX | -15.72% | $8.23B | +9.48% | 1.37% |
DUK | -14.81% | $90.88B | +16.65% | 3.59% |
CME | -14.54% | $99.01B | +39.76% | 3.87% |
MO | -14.26% | $98.96B | +28.98% | 6.98% |
HSY | -14.21% | $33.83B | -9.16% | 3.28% |
MDLZ | -14.09% | $87.76B | +3.58% | 2.73% |
WTRG | -14.03% | $10.35B | -1.10% | 3.50% |
MSEX | -13.67% | $976.83M | +4.31% | 2.48% |
KO | -13.42% | $302.72B | +10.49% | 2.83% |
AMT | -13.37% | $101.95B | +12.04% | 3.05% |
NOC | -13.32% | $71.10B | +13.32% | 1.72% |
EXC | -13.32% | $43.32B | +23.98% | 3.65% |
CL | -12.91% | $71.89B | -8.58% | 2.28% |
TU | -11.99% | $24.14B | +4.56% | 7.30% |
Finnhub
Glaukos Corporation added to Russell 2000 Growth-Defensive Index...
Finnhub
Glaukos Corporation added to Russell 2000 Defensive Index...
Yahoo
The iStent infinite Trabecular Micro-Bypass System Model iS3 is for minimising IOP in those with primary open-angle glaucoma.
Finnhub
ALISO VIEJO, Calif. - Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal...
Yahoo
ALISO VIEJO, Calif., June 25, 2025--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. Glaukos’ iStent® trabecular mic
Finnhub
Glaukos Corporation announced it has received European Union Medical Device Regulation certification for iStent infinite, along with several of its other leading micro-invasive glaucoma surgery ...
Current Value
$102.471 Year Return
Current Value
$102.471 Year Return